Lynparza Tablet
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Lynparza Tablet contains olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. Its labelling describes it as an oral treatment for certain cancers associated with BRCA gene mutations or homologous recombination repair (HRR) deficiency — including ovarian, breast, pancreatic and prostate cancer — where it is described as interfering with an enzyme cancer cells use to repair damaged DNA.
Product Information
The following description reflects information associated with olaparib and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of certain BRCA-mutated breast cancers
- Described for the treatment of certain ovarian cancers
- Described as maintenance therapy for BRCA-mutated metastatic pancreatic cancer and HRR-mutated metastatic prostate cancer
Described Dosage & Administration
- Taken by mouth with or without food, at the dose and schedule prescribed
- Tablets are swallowed whole — not crushed, chewed or split, per manufacturer guidance
- Taken at the same time each day; the prescribed dose should not be skipped, doubled or exceeded
Described Side Effects
Commonly described side effects include:
- Nausea and vomiting
- Fatigue
- Loss of appetite
- Diarrhoea
- Dizziness
- Described as possibly lowering red blood cell, platelet and white blood cell counts (anaemia, low platelets, low WBC)
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Manufacturer guidance describes regular blood tests during treatment
- Caution with driving or operating machinery if dizziness or fatigue occurs
- Effective contraception is described as necessary during treatment, as the medicine may harm an unborn baby
- Pregnancy, planned pregnancy or breastfeeding should be discussed with the prescriber
- Chest pain, rapid heartbeat, or new or worsening breathlessness or cough should be reported to a doctor promptly
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling, Lynparza Tablet contains olaparib and is described for certain BRCA- or HRR-associated ovarian, breast, pancreatic and prostate cancers, including as maintenance therapy. SDO Pharma has not independently verified these claims.
Its labelling notes that some medicines and supplements may interact with olaparib, so the prescriber should be told about all other medicines being taken. This does not replace the manufacturer’s prescribing information.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.